50
Participants
Start Date
July 3, 2023
Primary Completion Date
May 1, 2025
Study Completion Date
July 1, 2025
Trilaciclib
trilaciclib 240mg/m2 ivgtt d1 Q3w; anti-PD-1 antibody 200mg ivgtt d1 Q3w; Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w; carboplatin AUC=5 ivgtt d1 Q3w; Review every 2 cycles until the best efficacy or intolerable toxicity, usually 6-8 cycles;
RECRUITING
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing
QIAO LI
OTHER